TY  - BOOK
AU  - Moehler,Thomas
AU  - Goldschmidt,Hartmut
ED  - SpringerLink (Online service)
TI  - Multiple Myeloma
T2  - Recent Results in Cancer Research,
SN  - 9783540857723
AV  - RC254-282 
U1  - 616.994 23
PY  - 2011///
CY  - Berlin, Heidelberg
PB  - Springer Berlin Heidelberg
KW  - Medicine
KW  - Oncology
KW  - Hematology
KW  - Medicine & Public Health
KW  - Cancer Research
N1  - History and epidemiology -- Pathophysiology: Molecular biology of plasma cell disorders. Alterations in microenvironment -- Clinical Features: Imaging. Integrated innovative approach for diagnosis and staging -- Therapy: High-dose chemotherapy and ABSCT -- Allogeneic transplantation. Novel Drugs -- Immunotherapeutic approaches -- First-line treatment and maintenance -- Relapse -- Radiotherapy -- Kyphoplasty -- Supportive Therapy -- Appendix: Staging and prognosis systems
N2  - Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy. In particular, the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide means that multiple myeloma now stands at the forefront of advances in oncology drug development. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life
UR  - http://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-3-540-85772-3
ER  -